| Recent Advancement in the Treatment of Chronic Hepatitis C |
|
Tae Hun Kim1, June Sung Lee2 |
1Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul
2Department of Internal Medicine, Ilsanpaik Hospital, Inje University College of Medicine, Goyang, Korea |
| 만성 C형 간염 치료의 최근 발전 |
|
김태헌1, 이준성2 |
1이화여자대학교 의학전문대학원 내과학교실
2인제대학교 일산백병원 내과 |
Correspondence:
June Sung Lee, Tel: +82-31-910-7823, Fax: +82-31-910-7219, Email: jsleemd@paik.ac.kr
|
|
|
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Abstract |
|
Currently, the most widely prescribed standard therapy for chronic hepatitis C consists of pegylated-interferon combined with ribavirin. Although the response rate to interferon-based treatments has improved since interferon monotherapy was first combined with ribavirin, and then pegylated-interferon was adopted, patients eligible for this treatment are limited; the side effects are unbearable in some patients, and the response rates are still unsatisfactory for those who have unfavorable clinical features. Achievements in molecular research have led to the discovery of enormous molecules with anti-hepatitis C virus (HCV) activity. Telaprevir, boceprevir, simeprevir, and sofosbuvir have already been approved by the U.S. Food and Drug Administration and many new drugs are being evaluated in ongoing clinical trials. We review the clinical efficacy of approved new anti-HCV drugs, along with many promising treatment options under development. (Korean J Med 2014;86:563-569) |
| Key Words:
Chronic hepatitis C; Treatement |
| 주제어:
만성 C형 간염; 치료 |
|
PDF Links
Full text via DOI
Download Citation
